






Supplementary Figure 1 Results of meta-analysis and sensitivity analysis of tumor number on overall survival and progression-free survival. A: Results of meta-analysis of tumor number on overall survival; B: Results of sensitivity analysis of tumor number to overall survival; C: Results of meta-analysis of tumor number on progression-free survival; D: Results of sensitivity analysis of tumor number to progression-free survival.




Supplementary Figure 2 Results of meta-analysis and sensitivity analysis of tumour size on overall survival and progression-free survival. A: Results of meta-analysis of tumour size on overall survival; B: Results of sensitivity analysis of tumour size to overall survival; C: Results of meta-analysis of tumour size on progression-free survival; D: Results of sensitivity analysis of tumour size to progression-free survival.




Supplementary Figure 3 Results of meta-analysis and sensitivity analysis of microvascular invasion on overall survival and progression-free survival.


A: Results of meta-analysis of microvascular invasion on overall survival; B: Results of sensitivity analysis of microvascular invasion to overall survival; C: Results of meta-analysis of microvascular invasion on progression-free survival; D: Results of sensitivity analysis of microvascular invasion to progression-free survival.




Supplementary Figure 4 Results of meta-analysis and sensitivity analysis of Eastern Cooperative Oncology Group performance status on overall survival and progression-free survival. A: Results of meta-analysis of Eastern Cooperative Oncology Group performance status on overall survival; **B:** Results of sensitivity analysis of Eastern Cooperative Oncology Group performance status to overall survival; **C:** Results of meta-analysis of Eastern Cooperative Oncology Group performance status on progression-free survival; **D:** Results of sensitivity analysis of Eastern Cooperative Oncology Group performance status to progression-free survival.




Supplementary Figure 5 Results of meta-analysis and sensitivity analysis of Child-Pugh stage on overall survival and progression-free survival. A: Results of meta-analysis of Child-Pugh stage on overall survival; **B:** Results of sensitivity analysis of Child-Pugh stage to overall survival; **C:** Results of meta-analysis of Child-Pugh stage on progression-free survival; **D:** Results of sensitivity analysis of Child-Pugh stage to progression-free survival.



Supplementary Figure 6 Results of meta-analysis and sensitivity analysis of triple therapy on overall survival and progression-free survival. A: Results of meta-analysis of triple therapy on overall survival; **B:** Results of sensitivity analysis of triple therapy to overall survival; **C:** Results of meta-analysis of triple therapy on progression-free survival; **D:** Results of sensitivity analysis of triple therapy to progression-free survival.




Supplementary Figure 7 Results of meta-analysis and sensitivity analysis of Barcelona Clinic Liver Cancer stage on overall survival and progression-free survival. A: Results of meta-analysis of Barcelona Clinic Liver Cancer stage on overall survival; B: Results of sensitivity analysis of Barcelona Clinic Liver Cancer stage to overall survival; C: Results of meta-analysis of Barcelona Clinic Liver Cancer stage on progression-free survival; D: Results of sensitivity analysis of Barcelona Clinic Liver Cancer stage to progression-free survival.




Supplementary Figure 8 Results of meta-analysis and sensitivity analysis of extrahepatic metastases on overall survival and progression-free survival.


A: Results of meta-analysis of extrahepatic metastases on overall survival; B: Results of sensitivity analysis of extrahepatic metastases to overall survival; C: Results of meta-analysis of extrahepatic metastases on progression-free survival; D: Results of sensitivity analysis of extrahepatic metastases to progression-free survival.




Supplementary Figure 9 Results of meta-analysis and sensitivity analysis of alpha-fetoprotein on overall survival and progression-free survival. A: Results of meta-analysis of alpha-fetoprotein on overall survival; **B:** Results of sensitivity analysis of alpha-fetoprotein to overall survival; **C:** Results of meta-analysis of alpha-fetoprotein on progression-free survival; **D:** Results of sensitivity analysis of alpha-fetoprotein to progression-free survival.




Supplementary Figure 10 Results of meta-analysis and sensitivity analysis of hepatitis B virus on overall survival and progression-free survival. A: Results of meta-analysis of alpha-fetoprotein on overall survival; **B:** Results of sensitivity analysis of alpha-fetoprotein to overall survival; **C:** Results of meta-analysis of alpha-fetoprotein on progression-free survival; **D:** Results of sensitivity analysis of alpha-fetoprotein to progression-free survival.



Supplementary Figure 11 Results of meta-analysis and sensitivity analysis of age on overall survival and progression-free survival. A: Results of meta-analysis of age on overall survival; B: Results of sensitivity analysis of age to overall survival; C: Results of meta-analysis of age on progression-free survival; D: Results of sensitivity analysis of age to progression-free survival.



Supplementary Figure 12 Results of meta-analysis and sensitivity analysis of aspartate aminotransferase on overall survival and progression-free survival. A: Results of meta-analysis of aspartate aminotransferase on overall survival; B: Results of sensitivity analysis of aspartate aminotransferase to overall survival; C: Results of meta-analysis of aspartate aminotransferase on progression-free survival; D: Results of sensitivity analysis of aspartate aminotransferase to progression-free survival.



Supplementary Figure 13 Receiver operating characteristic curves for prediction models of Barcelona Clinic Liver Cancer staging system in the validation cohort. A: Overall survival; B: Progression-free survival.

Supplementary Table 1 Details of the Literature Search Strategy

(1) Web of science (June 1, 2025)

Search	Query	Results
#1	("transcatheter"[All Fields] AND ("arterialization"[All Fields] OR "arterializations"[All Fields] OR "arterialize"[All Fields] OR "arterialized"[All Fields] OR "arterializing"[All Fields] OR "arterially"[All Fields] OR "arterials"[All Fields] OR "arterie"[All Fields] OR "arteries"[MeSH Terms] OR "arteries"[All Fields] OR "arterial"[All Fields] OR "arteris"[All Fields] OR "artery"[All Fields] OR "arterious"[All Fields] OR "arterys"[All Fields] OR "arterys"[All Fields]) AND ("chemoembolic"[All Fields] OR "chemoembolisation"[All Fields] OR "chemoembolizations"[All Fields] OR "chemoembolism"[All Fields] OR "chemoembolization"[All Fields] OR "chemoembolizations"[All Fields] OR "chemoembolized"[All Fields])) OR (("transarterial"[All Fields] OR "transarterially"[All Fields]) AND ("chemoembolic"[All Fields] OR "chemoembolisation"[All Fields] OR "chemoembolizations"[All Fields] OR "chemoembolism"[All Fields] OR "chemoembolization"[All Fields] OR "chemoembolizations"[All Fields] OR "chemoembolized"[All Fields])) OR "TACE"[All Fields]	11897
#2	"lenvatinib"[Supplementary Concept] OR "lenvatinib"[All Fields]	3187
#3	#1 AND #2	363

(2) PubMed (June 1, 2025)

Search	Query	Results
--------	-------	---------

#1	((TS=(transcatheter arterial chemoembolization)) OR TS=(TACE)) OR TS = (Transarterial chemoembolization)	18897
#2	TS=(Lenvatinib) and Preprint Citation Index (Exclude-Database)	5383
#3	#1 AND #2	596

(3) Embase (June 1, 2025)

Search	Query	Results
#1	('transcatheter'/exp OR transcatheter) AND arterial AND ('chemoembolization'/exp OR chemoembolization)	5162
#2	tace	15665
#3	transarterial AND chemoembolization	11023
#4	#1 OR #2 OR #3	20466
#5	lenvatinib	10008
#6	#4 AND #5	780

(4) Cochrane Library (June 1, 2025)

Search	Query	Results
#1	("transcatheter arterial chemoembolization"):ti,ab,kw OR (Transarterial chemoembolization):ti,ab,kw OR (TACE):ti,ab,kw	1750

#2	Lenvatinib	769
#3	#1 and #2	71

Supplementary Table 2 Baseline characteristics of the 43 studies included in the systematic review and meta-analysis.

Study	Year	Country	Study design	Age (year; mean/median)	Male/f emale	No. of patients	Risk factors for OS and PFS
Biao Yang	2021	China	Prospective	55.1	104/12	116	Age, Gender, Microvascular invasion, Number of tumor, ECOG performance status, Child-Pugh, AFP, AST, ALT, Triple therapy, NLR, PLT, Extrahepatic metastases, Tumor size, HBV
Bo Sun	2022	China	Retrospective	53.3	71/12	83	Age, Gender, Number of tumor, ECOG performance status, Child-Pugh, AFP, AST, ALT, Triple therapy, NLR, PLT, ALBI, BCLC stage, Extrahepatic metastases, Tumor size, HBV
De-Yi Liu	2024	China	Retrospective	57	47/13	60	Age, Gender, Microvascular invasion, Number of tumor, ECOG performance status, Child-Pugh, AFP, AST, ALT, NLR, ALBI, Tumor size, NLR, Extrahepatic metastases, HBV
Dongdong Xia	2022	China	Retrospective	53	184/27	211	Age, Gender, Number of tumor, ECOG performance status, Child-Pugh, AFP, AST, ALT, Triple therapy, NLR, ALBI, Extrahepatic metastases, Tumor size, HBV
Hidekatsu Kuroda	2022	Japan	Retrospective	70.8	190/40	230	Age, Gender, Microvascular invasion, Number of tumor, ECOG performance status, Child-Pugh, Triple therapy, BCLC stage,

							Extrahepatic metastases, Tumor size, HBV
Hong-Xiao Wu	2024	China	Retrospective	57.5	33/8	41	ECOG performance status, Child-Pugh, Triple therapy
Hui Yang	2023	China	Retrospective	62.3	98/24	122	Age, Gender, Microvascular invasion, Number of tumor, ECOG performance status, Child-Pugh, AFP, Triple therapy, Extrahepatic metastases, Tumor size
Jiayun Jiang	2024	China	Retrospective	55.3	117/19	136	Age, Gender, Number of tumor, ECOG performance status, Child-Pugh, AFP, Triple therapy, BCLC stage, Extrahepatic metastases, Tumor size, Microvascular invasion, HBV
Jinfeng Wang	2023	China	Retrospective	57.1	92/13	105	Age, Gender, Number of tumor, Child-Pugh, AFP, AST, ALT, Triple therapy, BCLC stage, Extrahepatic metastases, Tumor size, Microvascular invasion, HBV
Juan Wu	2023	China	Retrospective	54.2	83/15	98	Age, Gender, Microvascular invasion, Number of tumor, ECOG performance status, Child-Pugh, AFP, Triple therapy, ALBI, Extrahepatic metastases, Tumor size
Juanfang Liu	2021	China	Retrospective	57.7	17/5	22	Age, Gender, Microvascular invasion, ECOG performance status, Child-Pugh, Triple therapy, BCLC stage, Extrahepatic metastases,

								HBV
Junning Liu	2023	China	Retrospective	52.5		58/8	66	Age, Gender, Number of tumor, Child-Pugh, AFP, Triple therapy, Extrahepatic metastases, Tumor size, HBV
Kun-Peng Ma	2024	China	Retrospective	57.7		89/13	102	Age, Gender, Microvascular invasion, Number of tumor, ECOG performance status, Child-Pugh, AFP, BCLC stage, Extrahepatic metastases, Tumor size, HBV
Lu Tang	2024	China	Retrospective	NA		57/7	64	Gender, Microvascular invasion, Number of tumor, AFP, Triple therapy, Tumor size
Mengran Lang	2023	China	Retrospective	NA		127/25	152	Age, Gender, Microvascular invasion, Number of tumor, ECOG performance status, Child-Pugh, AFP, Triple therapy, ALBI, BCLC stage, Extrahepatic metastases, Tumor size, HBV
Ming Jin	2024	China	Retrospective	NA		127/17	144	Age, Gender, Microvascular invasion, Number of tumor, ECOG performance status, Child-Pugh, AFP, AST, ALT, Triple therapy, BCLC stage, Tumor size, HBV
Mingyue Cai	2022	China	Retrospective	53.3		70/11	81	Age, Gender, Microvascular invasion, Number of tumor, ECOG performance status, Child-Pugh, AFP, Triple therapy, Extrahepatic metastases, Tumor size, HBV

Qin Shi	2023	China	Retrospective	NA	117/15	132	Age, Gender, Microvascular invasion, Number of tumor, ECOG performance status, Child-Pugh, AFP, Triple therapy, ALBI, BCLC stage, Extrahepatic metastases, Tumor size, HBV
Qing-Yun Xie	2022	China	Retrospective	56.7	79/25	104	Age, Gender, Number of tumor, Child-Pugh, AFP, Triple therapy, BCLC stage, Tumor size
Seiichi Mawatari	2022	Japan	Retrospective	74	67/21	88	Number of tumor, Triple therapy, Tumor size
Sheng Zhong	2025	China	Retrospective	45.1	263/31	294	Number of tumor, AFP, Triple therapy,ALBI, Tumor size
Shuping Qu	2022	China	Prospective	53	100/10	110	Age, Gender, Microvascular invasion, Number of tumor, ECOG performance status, Child-Pugh, AFP, Triple therapy, NLR, ALBI, BCLC stage, Extrahepatic metastases, Tumor size
Shuping Qu	2023	China	Prospective	51	57/6	63	Age, Gender, Microvascular invasion, Number of tumor, AFP, NLR, ALBI, BCLC stage, Extrahepatic metastases, Tumor size
Shu-Qun Li	2023	China	Retrospective	NA	37/4	41	Age, Gender, Number of tumor, ECOG performance status, Child-Pugh, AFP, AST, ALT, Triple therapy,PLT, ALBI, Extrahepatic metastases, Tumor size

Song Chen	2024	China	Retrospective	56.3	138/11	149	Age, Gender, Number of tumor, ECOG performance status, Child-Pugh, AFP, Tumor size
Uchida-Ko bayashi	2022	Japan	Retrospective	75	54/9	63	Age, Gender, AFP, Triple therapy, NLR, BCLC stage
Wei Sun	2024	China	Retrospective	58	51/16	67	ECOG performance status, Extrahepatic metastases, Number of tumor
Wei-Jun Wang	2023	China	Retrospective	58.8	130/9	139	Age, Gender, ECOG performance status, Child-Pugh, AFP, AST, ALT, Triple therapy, ALBI, Tumor size, HBV
Wenzhe Fan	2023	China	Retrospective	50.5	270/30	300	Age, Number of tumor, ECOG performance status, Child-Pugh, AFP, Triple therapy, Tumor size, HBV
Xiangye Ou	2024	China	Retrospective	NA	93/13	106	Age, Gender, Microvascular invasion, Number of tumor, ECOG performance status, AFP, AST,ALT, PLT, ALBI, Extrahepatic metastases, Tumor size, Child-Pugh, HBV
Xiaowei Li	2022	China	Retrospective	53	102/12	114	Age, Gender, Microvascular invasion, Number of tumor, Child-Pugh, AFP, BCLC stage, Extrahepatic metastases, Tumor size, HBV
Xiaoyan	2021	China	Prospective	56	52/12	64	Age, Gender, Child-Pugh, ECOG performance status,

Ding								Extrahepatic metastases, Tumor size
Xingzhi Li	2023	China	Retrospective	NA		89/5	94	Age, Microvascular invasion, Number of tumor, ECOG performance status, Child-Pugh, AFP, AST, ALT, ALBI, BCLC stage, Extrahepatic metastases, Tumor size, HBV
Xiumei Jiang	2024	China	Retrospective	NA		106/21	127	Age, Gender, Microvascular invasion, Number of tumor, Child-Pugh, AFP, ALT, Triple therapy, ALBI, BCLC stage, Extrahepatic metastases, Tumor size, HBV
Xuexian Zhang	2024	China	Retrospective	NA		71/14	85	Age, Gender, Microvascular invasion, Number of tumor, ECOG performance status, AFP, Triple therapy, BCLC stage, Tumor size, Child-Pugh, Extrahepatic metastases, HBV
Yan-Yu Wang	2023	China	Retrospective	57		57/8	65	Age, Gender, Microvascular invasion, Number of tumor, ECOG performance status, AFP, Triple therapy, BCLC stage, Extrahepatic metastases, Tumor size, Child-Pugh, AST, ALBI, HBV
Yu Yao	2025	China	Retrospective	NA		107/14	121	Age, Gender, Number of tumor, Child-Pugh, AFP, ALT, Triple therapy, PLT, Tumor size, HBV
Yujing Xin	2023	China	Retrospective	56		105/13	118	Age, Gender, Microvascular invasion, Number of tumor, ECOG

							performance status, AFP, Triple therapy, ALBI, Extrahepatic metastases, Tumor size, BCLC stage, HBV
Yushan Zhao	2024	China	Retrospective	NA	137/31	168	Age, Gender, Microvascular invasion, Number of tumor, Child-Pugh, AFP, Triple therapy, Extrahepatic metastases, Tumor size, HBV
Yuwa Ando	2021	Japan	Retrospective	73.5	78/10	88	Child-Pugh, Triple therapy, AFP
Yu-Xing Chen	2022	China	Retrospective	59.4	154/33	187	Age, Gender, Microvascular invasion, Number of tumor, Child-Pugh, AFP, Triple therapy, Tumor size
Zheng Zong	2024	China	Retrospective	NA	94/8	102	Age, Microvascular invasion, Child-Pugh, AFP, AST, ALT, Triple therapy, ALBI, BCLC stage, Extrahepatic metastases
Zhihong Tang	2024	China	Retrospective	51.5	226/22	248	Age, Gender, Child-Pugh, AFP, Triple therapy, BCLC stage, Tumor size, Microvascular invasion, Number of tumor

Supplementary Table 3 Assessment of cohort studies using Newcastle-Ottawa scale

Study	Year	Selection							Comparability	Exposure/outcome				Total score		
		Represent	activeness	Selection	of	Ascertainment	Outcome	not	Comparability	Assessment	Length	of	Adequacy		of	
		of cohort★		control cohort★		of exposure★	present at start★		of cohorts★★	of outcome★	follow★		follow up★		9	
Biao Yang	2021	★		★		★		★		★★		★		★		9
Bo Sun	2022	★		★		★		★		★		★		★		8
De-Yi Liu	2024	★		★		★		★		★		★		★		8
Dongdong Xia	2022	★		★		★		★		★★		★		★		9
Hidekatsu Kuroda	2022	★		★		★		★		★★		★		★		9
Hong-Xiao Wu	2024	★		★		★		★		★		★		★		7
Hui Yang	2023	★		★		★		★		★		★		★		8
Jiayun Jiang	2024	★		★		★		★		★★		★		★		9
Jinfeng Wang	2023	★		★		★		★		★★		★		★		9
Juan Wu	2023	★		★		★		★		★		★		★		7
Juanfang Liu	2021	★		★		★		★		★		★		★		8
Junning Liu	2023	★		★		★		★		★		★		★		8
Kun-Peng Ma	2024	★		★		★		★		★		★		★		8
Lu Tang	2024	★		★		★		★		★		★		★		7
Mengran Lang	2023	★		★		★		★		★★		★		★		9
Ming Jin	2024	★		★		★		★		★		★		★		7
Mingyue Cai	2022	★		★		★		★		★		★		★		7

Yushan Zhao	2024	★		★		★		★		★		★		★		★		★		8
Yuwa Ando	2021	★		★		★		★		★		★		★		★		★		8
Yu-Xing Chen	2022	★		★		★		★		★★		★		★		★		★		9
Zheng Zong	2024	★		★		★		★		★		★		★		★		★		8
Zhihong Tang	2024	★		★		★		★		★★		★		★		★		★		9

Supplementary Table 4 Results of meta-analyses of risk factors for outcome indicators overall survival and progression-free survival

Risk factors	Outcome	No. of articles (120)	Sample size	Heterogeneity test		Pooled results		
				<i>I</i> ²	<i>P</i> value	HR	95%CI	<i>P</i> value
Age	OS	22	2626	0%	0.906	0.99	0.98-1.00	0.015
	PFS	18	2080	0%	0.637	1.00	0.99-1.01	0.980
Gender	OS	33	3840	0%	0.761	1.11	0.97-1.28	0.142
	PFS	28	3254	25.8%	0.107	0.91	0.78-1.07	0.263
Microvascular invasion	OS	28	3269	25.8%	0.107	1.61	1.41-1.85	< 0.01
	PFS	22	2483	48%	0.007	1.38	1.18-1.62	< 0.01
Number of tumors	OS	22	2695	32.9%	0.069	1.22	1.06-1.40	< 0.01
	PFS	20	2521	33.9%	0.070	1.23	1.07-1.40	< 0.01
ECOG-PS	OS	21	2487	0%	0.768	1.30	1.12-1.52	< 0.01
	PFS	23	2377	0%	0.465	1.27	1.14-1.42	< 0.01
Child-Pugh	OS	30	3641	27.7%	0.083	1.48	1.26-1.74	< 0.01
	PFS	28	3177	40.5%	0.015	1.45	1.23-1.70	< 0.01
AFP	OS	32	4186	0%	0.501	1.55	1.40-1.72	< 0.01

AST	PFS	28	3372	15.6%	0.235	1.28	1.16-1.41	< 0.01
	OS	12	1266	0%	0.451	1.01	1.00-1.01	< 0.01
ALT	PFS	9	814	0%	0.999	1.00	1.00-1.00	0.996
	OS	13	1449	0%	0.602	1.00	1.00-1.00	0.512
Triple therapy	PFS	10	1001	0%	0.954	1.00	1.00-1.00	0.996
	OS	31	4066	24.3%	0.113	0.41	0.36-0.46	< 0.01
NLR	PFS	26	3226	55.7%	<0.01	0.45	0.39-0.53	< 0.01
	OS	7	706	83%	<0.01	1.30	0.98-1.71	0.066
PLT	PFS	3	253	66.7%	0.050	1.43	0.97-2.08	0.073
	OS	5	587	0%	0.813	1.00	1.00-1.00	0.995
ALBI	PFS	3	230	0%	0.970	0.93	0.46-1.85	0.829
	OS	18	1967	20%	0.215	1.01	0.97-1.05	0.629
BCLC stage	PFS	14	1656	0.4%	0.444	1.00	0.97-1.03	0.918
	OS	21	2402	6.2%	0.379	1.77	1.51-2.08	< 0.01
Extrahepatic metastases	PFS	17	2051	31%	0.109	1.36	1.15-1.60	< 0.01
	OS	26	3060	33.2%	0.063	1.40	1.23-1.60	< 0.01
	PFS	23	2441	58.9%	<0.01	1.26	1.07-1.50	< 0.01

Tumor size	OS	22	2885	53.7%	<0.01	1.07	1.01-1.13	0.033
	PFS	17	2152	42.5%	0.033	1.06	1.01-1.12	0.031
HBV	OS	24	2880	0%	0.974	1.36	1.17-1.58	< 0.01
	PFS	20	2356	0%	0.996	1.18	1.02-1.36	0.027

Supplementary Table 5 Results of published bias analyses by risk factor for outcome indicators overall survival and progression-free survival

Risk factors	Outcome	Egger's test	Begg's test
Age	OS	0.779	0.446
	PFS	0.686	0.622
Gender	OS	0.291	0.361
	PFS	0.525	0.953
Microvascular invasion	OS	0.062	0.028
	PFS	0.385	0.499
Number of tumors	OS	0.095	0.114
	PFS	0.218	0.581
ECOG performance status	OS	0.037	0.020
	PFS	0.029	0.011
Child-Pugh	OS	0.311	0.335
	PFS	0.303	0.418
AFP	OS	0.481	0.341
	PFS	0.374	0.087
AST	OS	0.078	1.000
	PFS	0.196	0.175
ALT	OS	0.042	0.891
	PFS	0.545	0.474
Triple therapy	OS	0.001	0.016
	PFS	0.086	0.234
NLR	OS	0.140	0.368
	PFS	0.194	1.000
PLT	OS	0.115	0.086
	PFS	0.196	1.000
ALBI	OS	0.001	0.211
	PFS	0.023	0.443

BCLC stage	OS	0.654	0.075
	PFS	0.139	0.232
Extrahepatic metastases	OS	0.007	0.011
	PFS	0.029	0.011
Tumor size	OS	0.013	1.000
	PFS	0.000	0.232
HBV	OS	0.047	0.189
	PFS	0.011	0.004

Supplementary Table 6 Baseline data of the validation cohort, *n* (%)

Characteristics	validation cohort
Sample size (<i>n</i>)	106
Age (year)	55.9 ± 12.5
Sex	
Male	92 (86.8)
Female	14 (13.2)
AFP	
< 400 ng/ml	57 (53.8)
≥ 400 ng/ml	49 (46.2)
HBV	
Negative	25 (23.6)
Positive	81 (76.4)
Number of tumors	
Single	25 (23.6)
Multiple	81 (76.4)
Microvascular invasion	
No	45 (42.5)
Yes	61 (57.5)
ECOG performance status	
≤ 0	16 (15.1)
> 0	90 (84.9)
Child-Pugh	
≤ A	67 (63.2)
> A	39 (36.8)
Triple therapy	
TACE + LEN	72 (67.9)
TACE + LEN + PD-1	34 (32.1)
BCLC stage	

≤B	34 (32.1)
>B	72 (67.9)
Extrahepatic metastases	
No	72 (67.9)
Yes	34 (32.1)
Follow-up (months)	13 (7.0-28.2)
